{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:09:52Z","timestamp":1792300192507,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China grants","doi-asserted-by":"crossref","award":["81830016"],"award-info":[{"award-number":["81830016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China grants","doi-asserted-by":"crossref","award":["81620108002"],"award-info":[{"award-number":["81620108002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China grants","doi-asserted-by":"crossref","award":["81771732"],"award-info":[{"award-number":["81771732"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China grants","doi-asserted-by":"crossref","award":["81770563"],"award-info":[{"award-number":["81770563"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China grants","doi-asserted-by":"crossref","award":["82070581"],"award-info":[{"award-number":["82070581"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China grants","doi-asserted-by":"crossref","award":["81500435"],"award-info":[{"award-number":["81500435"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12016-021-08833-w","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T16:03:09Z","timestamp":1611936189000},"page":"292-300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Serum Immunoglobulin G Levels Predict Biochemical and Histological Remission of Autoimmune Hepatitis Type 1: A Single-Center Experience and Literature Review"],"prefix":"10.1007","volume":"62","author":[{"given":"You","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengrui","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruqi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dekai","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Eric","family":"Gershwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"issue":"14","key":"8833_CR1","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1056\/NEJM199604043341406","volume":"334","author":"EL Krawitt","year":"1996","unstructured":"Krawitt EL (1996) Autoimmune hepatitis. N Engl J Med 334(14):897\u2013903","journal-title":"N Engl J Med"},{"issue":"1 Suppl","key":"8833_CR2","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1016\/j.jhep.2015.03.005","volume":"62","author":"MP Manns","year":"2015","unstructured":"Manns MP, Lohse AW, Vergani D (2015) Autoimmune hepatitis\u2014update 2015. J Hepatol 62(1 Suppl):S100\u2013S111","journal-title":"J Hepatol"},{"issue":"4","key":"8833_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","volume":"41","author":"D Vergani","year":"2004","unstructured":"Vergani D et al (2004) Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 41(4):677\u2013683","journal-title":"J Hepatol"},{"issue":"6","key":"8833_CR4","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.1840070626","volume":"7","author":"JC Homberg","year":"1987","unstructured":"Homberg JC et al (1987) Chronic active hepatitis associated with antiliver\/kidney microsome antibody type 1: a second type of \u201cautoimmune\u201d hepatitis. Hepatology 7(6):1333\u20131339","journal-title":"Hepatology"},{"issue":"1","key":"8833_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/0168-8278(95)80308-4","volume":"23","author":"AJ Czaja","year":"1995","unstructured":"Czaja AJ et al (1995) Frequency and significance of antibodies to histones in autoimmune hepatitis. J Hepatol 23(1):32\u201338","journal-title":"J Hepatol"},{"issue":"9214","key":"8833_CR6","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/S0140-6736(00)02166-8","volume":"355","author":"I Wies","year":"2000","unstructured":"Wies I et al (2000) Identification of target antigen for SLA\/LP autoantibodies in autoimmune hepatitis. Lancet 355(9214):1510\u20131515","journal-title":"Lancet"},{"issue":"1","key":"8833_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1478-3231.2011.02502.x","volume":"32","author":"AJ Montano-Loza","year":"2012","unstructured":"Montano-Loza AJ et al (2012) Prognostic implications of antibodies to Ro\/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int 32(1):85\u201392","journal-title":"Liver Int"},{"issue":"7","key":"8833_CR8","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1053\/j.gastro.2011.02.065","volume":"140","author":"B Hoeroldt","year":"2011","unstructured":"Hoeroldt B et al (2011) Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 140(7):1980\u20131989","journal-title":"Gastroenterology"},{"key":"8833_CR9","doi-asserted-by":"crossref","unstructured":"Mack CL et al (2019) Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology, .","DOI":"10.1002\/hep.31065"},{"key":"8833_CR10","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the L (2015)\u00a0EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol, 63(4): p. 971\u20131004.","DOI":"10.1016\/j.jhep.2015.06.030"},{"issue":"5","key":"8833_CR11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","volume":"63","author":"RD Soloway","year":"1972","unstructured":"Soloway RD et al (1972) Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 63(5):820\u2013833","journal-title":"Gastroenterology"},{"issue":"5","key":"8833_CR12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez F et al (1999) International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31(5):929\u2013938","journal-title":"J Hepatol"},{"issue":"6","key":"8833_CR13","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/hep.23584","volume":"51","author":"MP Manns","year":"2010","unstructured":"Manns MP et al (2010) Diagnosis and management of autoimmune hepatitis. Hepatology 51(6):2193\u20132213","journal-title":"Hepatology"},{"issue":"7","key":"8833_CR14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/ajg.2015.139","volume":"110","author":"HK Dhaliwal","year":"2015","unstructured":"Dhaliwal HK et al (2015) Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis. Am J Gastroenterol 110(7):993\u2013999","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"8833_CR15","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","volume":"22","author":"K Ishak","year":"1995","unstructured":"Ishak K et al (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22(6):696\u2013699","journal-title":"J Hepatol"},{"key":"8833_CR16","doi-asserted-by":"crossref","unstructured":"Lohse AW et al (2020) Second-line and third-line therapy for autoimmune hepatitis a position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. Journal of hepatology.","DOI":"10.1016\/j.jhep.2020.07.023"},{"issue":"6","key":"8833_CR17","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jhep.2005.06.006","volume":"43","author":"Y Miyake","year":"2005","unstructured":"Miyake Y et al (2005) Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 43(6):951\u2013957","journal-title":"J Hepatol"},{"issue":"10","key":"8833_CR18","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/apt.13584","volume":"43","author":"K Zachou","year":"2016","unstructured":"Zachou K et al (2016) A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. Aliment Pharmacol Ther 43(10):1035\u20131047","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"8833_CR19","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jhep.2010.12.032","volume":"55","author":"K Zachou","year":"2011","unstructured":"Zachou K et al (2011) Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol 55(3):636\u2013646","journal-title":"J Hepatol"},{"issue":"7","key":"8833_CR20","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/apt.15157","volume":"49","author":"P Santiago","year":"2019","unstructured":"Santiago P et al (2019) Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. Aliment Pharmacol Ther 49(7):830\u2013839","journal-title":"Aliment Pharmacol Ther"},{"key":"8833_CR21","doi-asserted-by":"crossref","unstructured":"Kanzler S et al (2001) Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol, 39(5): p. 339\u201341, 344\u20138.","DOI":"10.1055\/s-2001-13708"},{"issue":"8","key":"8833_CR22","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/MCG.0b013e318154af74","volume":"42","author":"S L\u00fcth","year":"2008","unstructured":"L\u00fcth S et al (2008) Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol 42(8):926\u2013930","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"8833_CR23","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jhep.2004.01.009","volume":"40","author":"AJ Czaja","year":"2004","unstructured":"Czaja AJ, Carpenter HA (2004) Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 40(4):646\u2013652","journal-title":"J Hepatol"},{"issue":"4","key":"8833_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/apt.12592","volume":"39","author":"AJ Czaja","year":"2014","unstructured":"Czaja AJ (2014) Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther 39(4):385\u2013406","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"8833_CR25","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/hep.27983","volume":"62","author":"MM Kirstein","year":"2015","unstructured":"Kirstein MM et al (2015) Prediction of short- and long-term outcome in patients with autoimmune hepatitis. Hepatology 62(5):1524\u20131535","journal-title":"Hepatology"},{"issue":"10","key":"8833_CR26","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1111\/apt.15248","volume":"49","author":"AJ Nicoll","year":"2019","unstructured":"Nicoll AJ et al (2019) Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. Aliment Pharmacol Ther 49(10):1314\u20131322","journal-title":"Aliment Pharmacol Ther"},{"key":"8833_CR27","doi-asserted-by":"crossref","unstructured":"van den Brand FF et al (2019) Increased mortality among patients with vs without cirrhosis and autoimmune hepatitis. Clin Gastroenterol Hepatol, 17(5): p. 940\u2013947 e2.","DOI":"10.1016\/j.cgh.2018.09.046"},{"issue":"1","key":"8833_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jhep.2009.02.026","volume":"51","author":"AJ Czaja","year":"2009","unstructured":"Czaja AJ (2009) Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 51(1):161\u2013167","journal-title":"J Hepatol"},{"key":"8833_CR29","doi-asserted-by":"crossref","unstructured":"Pape S et al (2020) Rapid response to treatment of autoimmune hepatitis associated with remission at 6 and 12 months. Clin Gastroenterol Hepatol, 18(7): p. 1609\u20131617 e4.","DOI":"10.1016\/j.cgh.2019.11.013"},{"issue":"Suppl 2","key":"8833_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000440752","volume":"33","author":"M Sebode","year":"2015","unstructured":"Sebode M, Schramm C (2015) AIH: which alternative for difficult-to-treat patients? Dig Dis 33(Suppl 2):83\u201387","journal-title":"Dig Dis"},{"issue":"3","key":"8833_CR31","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jhep.2014.10.018","volume":"62","author":"J Hartl","year":"2015","unstructured":"Hartl J et al (2015) Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. J Hepatol 62(3):642\u2013646","journal-title":"J Hepatol"},{"issue":"4","key":"8833_CR32","doi-asserted-by":"publisher","first-page":"498","DOI":"10.14309\/ajg.0000000000000538","volume":"115","author":"AM Moon","year":"2020","unstructured":"Moon AM et al (2020) Immunosuppression in autoimmune hepatitis: is there an end game? Am J Gastroenterol 115(4):498\u2013501","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"8833_CR33","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/hep.25658","volume":"56","author":"K Yoshizawa","year":"2012","unstructured":"Yoshizawa K et al (2012) Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology 56(2):668\u2013676","journal-title":"Hepatology"}],"updated-by":[{"DOI":"10.1007\/s12016-021-08853-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000}}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08833-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-021-08833-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08833-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T04:26:39Z","timestamp":1649478399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-021-08833-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["8833"],"URL":"https:\/\/doi.org\/10.1007\/s12016-021-08833-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12016-021-08853-6","asserted-by":"object"}]},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]},"assertion":[{"value":"4 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12016-021-08853-6","URL":"https:\/\/doi.org\/10.1007\/s12016-021-08853-6","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}